Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer

Area of Science:

• Nuclear oncology
• Radiopharmaceutical development
• Molecular imaging and therapy

Background:

• Overexpressed peptide receptors on human tumors present a viable target for cancer diagnostics and therapeutics.
• Peptide-based radiopharmaceuticals are emerging as a promising class of drugs for targeted cancer management.
• Advances in peptide synthesis and radiolabeling techniques facilitate the development of novel radiopharmaceuticals.

Purpose of the Study:

• To review recent advancements in the field of radiolabeled small peptides for cancer diagnosis and treatment.
• To highlight the potential of targeting specific peptide receptors overexpressed in tumors.
• To focus on the development and application of somatostatin and bombesin analogs as radiopharmaceuticals.

Main Methods:

• Utilizing solid-phase peptide synthesis for creating custom peptide structures.
• Employing a diverse range of bifunctional chelating agents for efficient radiolabeling.
• Investigating the use of various radionuclides for diagnostic imaging and radiotherapy.

Main Results:

• Development of a wide array of medicinally useful peptide radiopharmaceuticals.
• Identification of several key peptide targets, including somatostatin, bombesin, cholecystokinin/gastrin, neurotensin, and vasoactive intestinal peptide.
• Ongoing clinical investigations into the applications of these peptides in nuclear oncology.

Conclusions:

• Peptide-based radiopharmaceuticals hold significant potential for improving cancer diagnosis and therapy.
• Targeted radiolabeling of specific peptide receptors offers a precise approach to cancer management.
• Somatostatin and bombesin analogs are leading candidates for clinical translation in nuclear oncology.